natgillin/translations-raw huggingface dataset:
In embryofetal development studies, no malformations were observed following subcutaneous administration of up to 200 mg/kg/day in the rat and intramuscular administration up to 15 mg/kg/day in the rabbit.
V študijah embriofetalnega razvoja niso opažali malformacij po subkutani uporabi odmerkov do 200 mg/kg/dan pri podganah in po intramuskularni uporabi odmerkov do 15 mg/kg/dan pri kuncih.
Preparation of the diluted solution before infusion Targocid can be administered in the following infusion solutions:
Priprava razredčene raztopine pred infundiranjem Zdravilo Targocid je mogoče aplicirati z naslednjimi raztopinami za infundiranje:
Powder for solution for injection/infusion or oral solution also contains: sodium chloride, sodium hydroxide (for pH adjustment).
Prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino vsebuje tudi: natrijev klorid, natrijev hidroksid (za prilagoditev pH).
Teicoplanin has a limited spectrum of antibacterial activity (Gram positive).
Teikoplanin ima omejen spekter protibakterijskega delovanja (Grampozitiven).
In pleural fluid and subcutaneous fat tissue the tissue/serum ratios are comprised between 0.2 and 0.5.
V plevralni tekočini in podkožnem maščevju je razmerje tkivo/serum med 0,2 in 0,5.
Teicoplanin should not be administered by intraventricular use.
Teikoplanina se ne sme uporabljati intraventrikularno.
Teicoplanin has a limited spectrum of antibacterial activity (Gram-positive).
Teikoplanin ima omejen spekter protibakterijskega delovanja (grampozitivni).
Teicoplanin is not removed by haemodialysis and only slowly by peritoneal dialysis.
Teikoplanin se s hemodializo ne odstrani, s peritonealno dializo pa se odstrani le počasi.
Subcutaneous administration of teicoplanin at up to 40 mg/kg/day did not affect male and female fertility in the rat.
Subkutana uporaba teikoplanina v odmerkih do 40 mg/kg/dan pri podganah ni vplivala na plodnost samcev in samic.
During treatment you may have tests to check your kidneys and/or your hearing.
Med zdravljenjem boste morda opravili preiskave za kontrolo ledvic, sluha ali obojega.
The reconstituted solution may be injected directly or alternatively further diluted.
Pripravljeno raztopino je mogoče injicirati neposredno, mogoče pa jo je še dodatno redčiti.
Since teicoplanin is mainly excreted by the kidney, the dose of teicoplanin must be adapted in patients with renal impairment (see section 4.2).
Ker se teikoplanin v glavnem izloča skozi ledvice, zato je treba bolnikom z okvaro ledvic odmerek teikoplanina prilagoditi (glejte poglavje 4.2).
• Slowly inject the entire content of the supplied solvent into the powder vial.
• Počasi injicirajte celotno količino priloženega vehikla v vialo s praškom.
This effect was not reported at 50 mg/kg/day A peri and postnatal study in rats showed no effects on the fertility of the F1 generation or on the survival and development of the F2 generation following subcutaneous administration of up to 40 mg/kg/day.
Peri- in postnatalna študija pri podganah ni pokazala vpliva na plodnost generacije F1 ali na preživetje in razvoj generacije F2 po subkutani uporabi odmerkov do 40 mg/kg/dan.
Therefore, this SmPC, labelling and package leaflet may not necessarily represent the current text.
Zato ta Povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo ni nujno zadnje veljavno besedilo.
• In mild and moderate renal insufficiency (creatinine clearance 30-80 mL/min): maintenance dose should be halved, either by administering the dose every two days or by administering half of this dose once a day.
• Pri blagi do zmerni insuficienci ledvic (očistek kreatinina 30-80 ml/min): vzdrževalni odmerek je treba prepoloviti, bodisi z uporabo odmerka na dva dni bodisi z uporabo pol tega odmerka enkrat na dan.
Teicoplanin distributed mainly in lung, myocardium and bone tissues with tissue/serum ratios superior to 1.
Teikoplanin se porazdeli predvsem v pljuča, miokard in kostno tkivo; razmerje tkivo/serum presega 1.
The solvent is a clear and colourless solution.
Vehikel je bistra in brezbarvna raztopina.
• complicated skin and soft tissue infections,
• zapletene okužbe kože in mehkih tkiv,
• 0.18% sodium chloride and 4% glucose solution
• raztopina 0,18 % natrijevega klorida in 4 % glukoze
• feeling dizzy or headache
• omotica ali glavobol
• In severe renal insufficiency (creatinine clearance less than 30 mL/min) and in haemodialysed patients: dose should be one-third the usual dose, either by administering the initial unit dose every third day or by administering one-third of this dose once a day.
• Pri hudi insuficienci ledvic (očistek kreatinina manj kot 30 ml/min) in bolniki na hemodializi: odmerek mora biti eno tretjino običajnega, bodisi z uporabo uvodnega posameznega odmerka vsak tretji dan bodisi z uporabo ene tretjine tega odmerka enkrat na dan. Hemodializa ne odstrani teikoplanina.
Teicoplanin does not readily penetrate into the cerebrospinal fluid (CSF).
Teikoplanin težko prodre v cerebrospinalno tekočino.
Susceptibility
Občutljivost
Resistant
Odporni
They will decide whether or not you can keep breast-feeding, while you are given Targocid.
Presodil bo, ali lahko med prejemanjem zdravila Targocid nadaljujete z dojenjem.
The intravenous injection may be administered either as a bolus over 3 to 5 minutes or as a 30-minute infusion.
Intravensko injekcijo je mogoče dati v bolusu v 3 do 5 minutah ali v 30-minutni infuziji.
Each vial contains either 100 mg, 200 mg or 400 mg teicoplanin.
Ena viala vsebuje 100 mg, 200 mg ali 400 mg teikoplanina.
Patients receiving teicoplanin in conjunction with or sequentially with other medicinal products with known neurotoxic/ototoxic potential (aminoglycosides, ciclosporin, cisplatin, furosemide and ethacrynic acid) should be carefully monitored and the benefit of teicoplanin evaluated if hearing deteriorates.
Bolnike, ki teikoplanin prejemajo skupaj ali v zaporedju z drugimi potencialno nevrotoksičnimi/ototoksičnimi zdravili (aminoglikozidi, ciklosporinom, cisplatinom, furosemidom ali etakrinsko kislino), je treba skrbno kontrolirati; če se jim sluh poslabša, je treba oceniti korist zdravljenja s teikoplaninom.
• 0.45% sodium chloride and 5% glucose solution
• raztopina 0,45 % natrijevega klorida in 5 % glukoze
Diarrhoea, vomiting, nausea
Bolezni prebavil driska, bruhanje, navzea
Stevens-Johnson syndrome, erythema multiforme, angioedema, dermatitis exfoliative, urticaria (see section
toksična epidermalnanekroliza, Stevens-Johnsonov sindrom, multiformni eritem, angioedem, eksfoliativni dermatitis, urtikarija (glejte poglavje 4.4)
Red man syndrome (e.g. Flushing of the upper part of the body) (see section 4.4).
Bolezni kože in podkožja izpuščaj, eritem, srbenje sindrom rdečega moža (npr. zardevanje zgornjega dela telesa) (glejte poglavje 4.4).
After six daily intramuscular administrations of 200 mg the mean (SD) maximum teicoplanin concentration (Cmax) amounts to 12.1 (0.9) mg/L and occurs at 2 hours after administration.
Po šestih dneh intramuskularne uporabe 200 mg je povprečna (standardni odklon) največja koncentracija teikoplanina (Cmax) 12,1 (0,9) mg/l in je dosežena 2 uri po dajanju zdravila.
Superinfection (overgrowth of non-susceptible organisms)
Infekcijske in parazitske bolezni absces superinfekcija (razrast neobčutljivih organizmov)
Patients with renal insufficiency, and/or in those receiving teicoplanin in conjunction with or sequentially with other medicinal products with known nephrotoxic potential (aminoglycosides, colistin, amphotericin B, ciclosporin, and cisplatin) should be carefully monitored, and should include auditory tests.
Bolnike z insuficienco ledvic in/ali bolnike, ki teikoplanin prejemajo skupaj ali v zaporedju z drugimi potencialno nefrotoksičnimi zdravili (aminoglikozidi, kolistinom, amfotericinom B, ciklosporinom, cisplatinom), je treba skrbno kontrolirati; spremljanje mora vključevati preiskave sluha.
• hospital acquired pneumonia,
• v bolnišnici dobljena pljučnica,
Primary packaging:
Priprava raztopine:
• raised in blood levels of creatinine (to monitor your kidney)
• zvišana koncentracija kreatinina v krvi (za kontrolo ledvic)
Anaphylactic reaction (anaphylaxis) (see section 4.4)
Bolezni imunskega sistema anafilaktična reakcija (anafilaksija) (glejte poglavje 4.4)
In blister fluids, synovial fluid and peritoneal fluid the tissue/serum ratios ranged from 0.5 to 1.
V tekočini mehurjev, sinovijski tekočini in peritonealni tekočini je bilo razmerje tkivo/serum od 0,5 do 1.
Fertility Animal reproduction studies have not shown evidence of impairment of fertility.
Plodnost Študije sposobnosti razmnoževanja pri živalih niso pokazale okvare plodnosti.
However, in the rat, there was an increased incidence of stillbirths at doses of 100 mg/kg/day and above and neonatal mortality at 200 mg/kg/day.
Vendar pa se je pri podganah pri odmerkih 100 mg/kg/dan in več povečala incidenca mrtvoskotenosti in pri 200 mg/kg/dan neonatalna umrljivost.
How to use Targocid
Kako uporabljati zdravilo Targocid
Elimination of teicoplanin from peritoneal fluid occurs at the same rate as from serum.
Iz peritonealne tekočine se teikoplanin odstranjuje enako hitro kot iz seruma.
Teicoplanin is administered by parenteral route (intravenously or intramuscularly).
Teikoplanin se daje parenteralno (intravensko ali intramuskularno).
Only clear and yellowish solutions should be used.
Uporabiti se sme le bistro ali rumeno raztopino.
The powder is a spongy ivory coloured homogeneous mass.
Prašek je gobasta, homogena masa slonokoščene barve.
If you stop having Targocid Do not stop having this medicine without first talking to your doctor, pharmacist or nurse.
Ne nehajte prejemati tega zdravila, ne da bi se prej posvetovali z zdravnikom, farmacevtom ali medicinsko sestro.
Unchanged form of teicoplanin is the main compound identified in plasma and urine, indicating minimal metabolism.
Glavna spojina v plazmi in urinu je nespremenjeni teikoplanin; to kaže na minimalno presnovo.
Elimination half-life of teicoplanin varies from 100 to 170 hours in the most recent studies where blood sampling duration is about 8 to 35 days.
V najnovejših študijah, v katerih je vzorčenje krvi trajalo okrog 8 do 35 dni, je bil eliminacijski razpolovni čas teikoplanina od 100 do 170 ur.
Life-threatening or even fatal cutaneous reactions Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have been reported with the use of teicoplanin.
Med uporabo teikoplanina so bile opisane življenje ogrožujoče ali celo smrtne kožne reakcije, npr. Stevens-Johnsonov sindrom (SJS) in toksična epidermalna nekroliza (TEN).
400 mg intravenous or intramuscular (this equates to approximately 6 mg/kg body weight) every 12 hours for 3 administrations
400 mg intravensko ali intramuskular no (to ustreza približno 6 mg/kg telesne mase) na 12 ur za 3 aplikacije
800 mg intravenous (this equates to approximately 12 mg/kg body weight) every 12 hours for 3 to 5 administrations
800 mg intravensko (to ustreza približno 12 mg/kg telesne mase) na 12 ur za 3 do 5 aplikacij
Fluorescence Polarization Immunoassay (FPIA) method.
Polarization Immunoassay).
Inherently resistant bacteria All Gram-negative bacteria Other bacteria
Inherentno odporne bakterije Vse gramnegativne bakterije Druge bakterije Chlamydia spp.
Water for injections [See Annex I - To be completed nationally]
Vehikel voda za injekcije [Glejte Prilogo I - Izpolni država članica]
Common (may affect up to 1 in 10 people)
Pogosti (pojavijo se lahko pri največ 1 od 10 oseb)
IE IE
/l.
This SmPC, labelling and packages leaflet is the version valid at the time of Commission decision.
Ta verzija Povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo je veljavna ob izdaji Sklepa komisije.
After a maintenance dose of 12 mg/kg once daily Ctrough values range from 18 to 30 mg/L.
Po vzdrževalnem odmerku 12 mg/kg enkrat na dan so vrednosti Cnajnižja od 18 do 30 mg
The solvent is packaged in Type I, colourless glass ampoule.
Vehikel je pakiran v ampulo iz brezbarvnega stekla tipa I.
Infection caused by ‘Clostridium difficile' bacteria The recommended dose is 100 to 200 mg by mouth, twice a day for 7 to 14 days.
Okužba, ki jo povzroča bakterija Clostridium difficile Priporočeni odmerek je od 100 do 200 mg peroralno (zaužitje) dvakrat na dan v trajanju od 7 do 14 dni.
• For endocarditis and other severe infections, teicoplanin trough levels of 15-30 mg/L when measured by HPLC, or 30-40 mg/L when measured by FPIA method.
• Za endokarditis in druge hude okužbe: najnižja koncentracija teikoplanina 15-30 mg/l izmerjena s
If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before you are given Targocid.
Če kaj od naštetega velja za vas (ali če ste negotovi), se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden dobite zdravilo Targocid.
As with other glycopeptides, ototoxicity (deafness and tinnitus) has been reported in patients treated with teicoplanin (see section 4.8).
Tako kot med uporabo drugih glikopeptidov je tudi pri bolnikih, zdravljenih s teikoplaninom, opisana ototoksičnost (naglušnost in tinitus) (glejte poglavje 4.8).
• For people with severe kidney problems or on haemodialysis - the maintenance dose will be given every three days, or one-third of the maintenance dose will be given once a day.
• Osebe s hudimi težavami z ledvicami in osebe na hemodializi dobijo vzdrževalni odmerek vsak tretji dan ali tretjino vzdrževalnega odmerka enkrat na dan.
They may also cause hearing problems and/or kidney problems.
Lahko tudi povzročijo težave s sluhom, težave z ledvicami ali oboje.
• Week two: 20 mg/L in every other dialysis bag
• drugi teden: 20 mg/l v vsako drugo dializno vrečko,
1 powder vial
1 viala s praškom
Pharmacokinetic/Pharmacodynamic relationship
Razmerje farmakokinetika/farmakodinamika
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution has taken place in controlled and validated aseptic conditions.
Če ni uporabljeno takoj, so čas shranjevanja med uporabo in pogoji pred uporabo odgovornost uporabnika; čas običajno ne sme presegati 24 ur pri temperaturi od 2 do 8 °C, razen če ni priprava opravljena v nadzorovanih in preverjenih aseptičnih pogojih.
The reconstituted solution may be injected directly or alternatively further diluted, or orally administered.
Pripravljeno raztopino se lahko injicira neposredno, lahko pa se jo dodatno razredči, ali se jo uporabi peroralno.
Uncommon (may affect up to 1 in 100 people)
Občasni (pojavijo se lahko pri največ 1 od 100 oseb)
If you have kidney problems, your dose will usually need to be lowered after the fourth day of treatment:
Odrasli in starejši bolniki, ki imajo težave z ledvicami Če imate težave z ledvicami, je treba odmerek po četrtem dnevu zdravljenja praviloma znižati:
• swelling and clotting in a vein
• oteklost in strdek v veni
• For people with mild and moderate kidney problems - the maintenance dose will be given every two days, or half of the maintenance dose will be given once a day.
• Osebe z blagimi ali zmernimi težavami z ledvicami dobijo vzdrževalni odmerek vsak drugi dan ali pol vzdrževalnega odmerka enkrat na dan.
One single dose of 10 mg/kg body weight administered intravenously every 12 hours, repeated 3 times.
En odmerek 10 mg/kg telesne mase intravensko na 12 ur; to je treba ponoviti 3-krat.
Renal failure has been reported in patients treated with teicoplanin (see section 4.8).
Pri bolnikih, zdravljenih s teikoplaninom, so poročali o odpovedi ledvic (glejte poglavje 4.8).
Streptococci in the viridans group a b Anaerobic Gram-positive bacteria Clostridium difficile a
Anaerobne grampozitivne bakterije Clostridium difficile a
After a loading dose of 6 mg/kg administered intravenously every 12 hours for 3 to 5 administrations, Cmax values range from 60 to 70 mg/L and Ctrough are usually above 10 mg/L.
Po polnilnem odmerku 6 mg/kg intravensko na 12 ur za 3 do 5 aplikacij je Cmax od 60 do 70 mg/l in Cnajnižja po navadi nad 10 mg/l.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.
Če ni uporabljeno takoj, so čas shranjevanja med uporabo in pogoji pred uporabo odgovornost uporabnika; čas običajno ne sme presegati 24 ur pri temperaturi od 2 do 8 °C, razen če ni priprava/redčenje opravljeno v nadzorovanih in preverjenih aseptičnih pogojih.
• Week three: 20 mg/L in the overnight dialysis bag.
• tretji teden: 20 mg/l v dializno vrečko za čez noč.
For instructions on reconstitution and dilution of the medicinal product before administration, see section
Za navodila o pripravi in razredčenju zdravila pred uporabo glejte poglavje 6.6.
Serious, life-threatening hypersensitivity reactions, sometimes fatal, have been reported with teicoplanin (e.g. anaphylactic shock).
S teikoplaninom so bile opisane resne, življenje ogrožujoče preobčutljivostne reakcije, včasih s smrtnim izidom (npr. anafilaktični šok).
Other side effects Talk to your doctor, pharmacist or nurse if you get any of these:
Drugi neželeni učinki Posvetujte se z zdravnikom, farmacevtom ali medicinsko sestro, če se vam pojavi kaj od naslednjega:
• water tablets (such as furosemide) - also called ‘diuretics' which may cause hearing problems and/or kidney problems.
• tablete za odvajanje vode (na primer furosemid) - takšna zdravila imenujemo tudi "diuretiki";
Clostridium difficile infection-associated diarrhea and colitis The recommended dose is 100-200 mg administered orally twice a day for 7 to 14 days.
Driska in kolitis, povezana z okužbo s Clostridium difficile Priporočeni odmerek je od 100 do 200 mg peroralno dvakrat na dan v trajanju od 7 do 14 dni.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte s svojim zdravnikom, s farmacevtom ali z medicinsko sestro.
The reconstituted solution may also be given by mouth.
Pripravljeno raztopino je mogoče dati tudi peroralno.
• bone and joint infections,
• okužbe kosti in sklepov,
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL OF POWDER VIAL
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH NALEPKA VIALE S PRAŠKOM
Only the infusion should be given in babies from birth to the age of 2 months.
Dojenčki od rojstva do starosti 2 mesecev smejo zdravilo dobiti le v infuziji.
EXP Read the leaflet for the shelf life of the reconstituted medicine.
EXP Za rok uporabnosti pripravljenega zdravila glejte navodilo za uporabo.
The starting dose is 6 mg for every kilogram of body weight, as a single injection into a vein, followed by:
Peritonitis pri bolnikih na peritonealni dializi Začetni odmerek je 6 mg na kilogram telesne mase v enkratni injekciji v veno; temu sledi:
• Maintenance dose: 6 to 10 mg for every kilogram of body weight, given once a day, by injection into a vein.
• Vzdrževalni odmerek: od 6 do 10 mg na kilogram telesne mase enkrat na dan z injekcijo v veno.
Volume withdrawable from the solvent ampoule for reconstitution
Količina, ki jo je mogoče izvleči iz ampule z vehiklom za pripravo
• cisplatin - a medicine that treats malignant tumors which may cause hearing problems and/or kidney problems
• cisplatin - zdravilo za zdravljenje malignih tumorjev, ki lahko povzroči težave s sluhom, težave z ledvicami ali oboje.
When administered by oral route teicoplanin is not absorbed from the gastrointestinal tract.
Peroralno uporabljeni teikoplanin se ne absorbira iz prebavil.
Powder for solution for injection/infusion or oral solution: spongy ivory coloured homogeneous mass Solvent: clear, colourless liquid.
Prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino: gobasta, homogena masa slonokoščene barve.
• you are taking other medicines which may cause hearing problems and/or kidney problems.
• če jemljete druga zdravila, ki lahko povzročijo težave s sluhom, težave z ledvicami ali oboje.
After a maintenance dose of 6 mg/kg administered once daily Cmax and Ctrough values are approximately 70 mg/L and 15 mg/L, respectively.
Po vzdrževalnem odmerku 6 mg/kg enkrat na dan je Cmax približno 70 mg/l in Cnajnižja približno 15 mg/l.
• The active substance is teicoplanin.
• Zdravilna učinkovina je teikoplanin.
Where appropriate, teicoplanin should be administered in combination with other antibacterial agents.
Teikoplanin je treba uporabiti v kombinaciji z drugimi protibakterijskimi zdravili, kadar je to primerno.
• ciclosporin - a medicine that affects the immune system which may cause hearing problems and/or kidney problems
• ciklosporin - zdravilo, ki vpliva na imunski sistem; povzroči lahko težave s sluhom, težave z ledvicami ali oboje.
Tell your doctor or nurse straight away, if you notice any of the following serious side effects - you may need urgent medical treatment:
Če opazite katerega od naslednjih resnih neželenih učinkov, takoj obvestite zdravnika ali medicinsko sestro - morda boste potrebovali nujno zdravniško pomoč:
• Starting dose (on the first day): 16 mg for every kilogram of body weight, as an infusion through a drip into a vein.
• Začetni odmerek (prvi dan): 16 mg na kilogram telesne mase kot kapalna infuzija v veno.
- Complicated skin and soft tissue infections
- Zapletene okužb kože in mehkih tkiv - Pljučnica - Zapletene okužbe sečil
After reconstitution, the solution will contain 100 mg teicoplanin in 1.5 mL.
Po pripravi bo raztopina vsebovala 100 mg teikoplanina v 1,5 ml.
Deafness, hearing loss (see section tinnitus, vestibular disorder
Ušesne bolezni, vključno z motnjami labirinta naglušnost, izguba sluha (glejte poglavje 4.4), tinitus, vestibularne motnje
Rare (≥1/10,000 to
Redki do < 1/1.000)
(e.g. progressive skin rash often with blisters or mucosal lesions) are present teicoplanin treatment should be discontinued immediately.
Če se pojavijo simptomi ali znaki SJS ali TEN (npr. napredujoč kožni izpuščaj, pogosto z mehurji ali spremembami na sluznici), je treba zdravljenje s teikoplaninom nemudoma končati.
• amphotericin B - a medicine that treats fungal infections which may cause hearing problems and/or kidney problems
• amfotericin B - zdravilo za zdravljenje glivičnih okužb, ki lahko povzroči težave s sluhom, težave z ledvicami ali oboje.
For intramuscular, intravenous or oral uses
za intramuskularno, intravensko ali peroralno uporabo
• Pain
• bolečine
• peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD), • bacteraemia that occurs in association with any of the indications listed above.
• peritonitis, povezan s kontinuirano ambulantno peritonealno dializo CAPD,
What Targocid looks like and contents of the pack Targocid is a powder for solution for injection/infusion or oral solution.
Izgled zdravila Targocid in vsebina pakiranja Zdravilo Targocid je prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino.
PHARMACEUTICAL FORM AND CONTENTS Powder for solution for injection/infusion or oral solution 1 powder vial
FARMACEVTSKA OBLIKA IN VSEBINA Prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino 1 viala s praškom
For Targocid, powder for solution for injection/infusion or oral solution What Targocid contains
Za zdravilo Targocid prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino Kaj vsebuje zdravilo Targocid
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL OF SOLVENT VIAL
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH NALEPKA VIALE Z VEHIKLOM
- Bone and joint infections
- Okužbe kosti in sklepov
Tell your doctor if you are breast-feeding, before being given this medicine.
Če dojite, morate to povedati zdravniku, preden dobite to zdravilo.
Teicoplanin should be administered by the intravenous or intramuscular route.
Teikoplanin je treba uporabljati intravensko ali intramuskularno.